Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R. Simó, E. Carrasco, M. García-Ramírez, C. Hernández.
Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.
Curr Diabet Rev, 2 (2006), pp. 71-98
[2.]
M.B. Grant, A. Afzal, P. Spoerri, H. Pan, L.C. Shaw, R.M. Mames.
The role of growth factors in the pathogenesis of diabetic retinopathy.
Expert Opin Investig Drugs, 13 (2004), pp. 1275-1293
[3.]
C. Hernández, R.M. Segura, A. Fonollosa, E. Carrasco, G. Francisco, R. Simó.
Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy.
Diabet Med, 22 (2005), pp. 719-722
[4.]
N. Ferrara.
Vascular endothelial growth factor: basic science and clinical progress.
Endocr Rev, 25 (2004), pp. 5881-6611
[5.]
C. Treins, S. Giorgetti-Peraldi, J. Murdaca, E. Van Obberghen.
Regulation of vascular endothelial growth factor expression by advanced glycation end products.
J Biol Chem, 276 (2001), pp. 43836-43841
[6.]
H. Ozaki, A.Y. Yu, N. Della, K. Ozati, J.D. Luna, H. Yamada, et al.
Hypoxia inducible factor-1 alpha is increased in ischemic retina: temporal and spatial correlation with VEGF.
Invest Ophthalmol Vis Sci, 40 (1999), pp. 182-189
[7.]
V. Poulaki, W. Qin, A.M. Joussen, P. Hurlbut, S.S. Wiegand, J. Rudge, et al.
Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF.
J Clin Invest, 109 (2002), pp. 805-815
[8.]
R.B. Caldwell, M. Bartoli, M.A. Behzadian, A.F. El-Kemessy, H. Al- Shobracuey, D.H. Platt, et al.
Vascular endotelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.
Diabetes Metab Res Rev, 19 (2003), pp. 442-455
[9.]
L. Aiello, R. Avery, P. Arrigg, B.A. Keyt, H.D. Jampel, S.T. Shah, et al.
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
N Engl J Med, 331 (1994), pp. 1480-1487
[10.]
R. Burgos, R. Simó, L. Audí, C. Mateo, J. Mesa, M. García-Ramírez, et al.
Vitreous levels of vascular endotelial growth factor are not nfluenced by its serum concentration in diabetic retinopathy.
Diabetologia, 40 (1997), pp. 1107-1109
[11.]
C. Hernández, R. Burgos, A. Cantón, J. García-Arumí, R.M. Segura, R. Simó.
Vitreous levels of vascular adhesion molecule and vascular endotelial growth factor in patients with proliferative diabetic retinopathy: a case-control study.
Diabetes Care, 24 (2001), pp. 516-521
[12.]
R. Simó, A. Lecube, R.M. Segura, J. García-Arumí, C. Hernández.
Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy.
Am J Ophthalmol, 134 (2002), pp. 376-382
[13.]
D. Le Roith, C. Bondy, S. Yakar, J.L. Liu, A. Butler.
The somatomedin hypothesis: 2001.
Endocr Rev, 22 (2001), pp. 53-74
[14.]
C. Gerhardinger, K.D. McClure, G. Romeo, F. Podesta, M. Lorenzi.
IGF-1 mRNA and signalling in the diabetic retina.
Diabetes, 50 (2001), pp. 175-183
[15.]
G.M. Seigel, L. Chiu, A. Paxhia.
Inhibition of neuroretinal cell death by insulin-like growth factor-1 and its analogs.
Mol Vis, 31 (2000), pp. 157-163
[16.]
S.H. Wilson, M.I. Davis, S. Caballero, M.B. Grant.
Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy.
Growth Horm IGF Res, 11 (2001), pp. S53-S59
[17.]
A. Hellstrom, B. Carlsson, A. Niklasson, K. Segnestam, M. Boguszecusti, L. De Locerda, et al.
IGF-I is critical for normal vascularization of the human retina.
J Clin Endocrinol Metab, 87 (2002), pp. 3413-3416
[18.]
R. Simó, C. Hernández, R.M. Segura, J. García-Arumí, L. Sararols, R. Burgos, et al.
Free IGF-I in the vitreous fluid of diabetic patients with proliferative diabetic retinopathy. A case-control study.
Clin Sci (Lond), 104 (2003), pp. 223-230
[19.]
L.E.H. Smith, J.J. Kopchick, W. Chen, J. Knapp, F. Kinose, D. Doley, et al.
Essential role of growth hormone in ischemia-induced retinal neovascularization.
Science, 276 (1997), pp. 1706-1709
[20.]
L.E.H. Smith, W. Shen, C. Perruzzi, S. Soker, F. Kinose, X. Xu, et al.
Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor.
Nature Med, 5 (1999), pp. 1390-1395
[21.]
R.P. Danis, D.P. Bingaman.
Insulin-like growth factor-1 retinal microangiopathy in the pig eye.
Ophthalmology, 104 (1997), pp. 1661-1669
[22.]
J. Ruberte, E. Ayuso, M. Navarro, A. Corretero, V. Nachez, V. Houngot, et al.
Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease.
J Clin Invest, 113 (2004), pp. 1149-1157
[23.]
W.L. Lowe, R.Z. Florkiewicz, M.A. Yorek, R.G. Spanheimer, B.N. Albrecht.
Regulation of growth factor mRNA levels in eyes of diabetic rats.
Metabolism, 44 (1995), pp. 1038-1045
[24.]
R. Burgos, C. Mateo, R. Cantón, C. Hernández, J. Mesa, R. Simó.
Vitreous levels of IGF-1, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy. A case-control study.
Diabetes Care, 23 (2000), pp. 80-83
[25.]
T. Kondo, D. Vicent, K. Suzuma, M. Yanagisacua, G.L. King, M. Holzenberg, et al.
Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization.
J Clin Invest, 111 (2003), pp. 1835-1842
[26.]
I. Grierson, L. Heathcote, P. Hiscott, P. Hogg, M. Briggs, S. Hagan.
Hepatocyte growth factor/scatter factor in the eye.
Prog Retin Eye Res, 19 (2000), pp. 779-802
[27.]
Y. Katsura, T. Okano, M. Noritake, H. Kosono, H. Nishigori, S. Kado, et al.
Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders.
Diabetes Care, 21 (1998), pp. 1759-1763
[28.]
M. Nishimura, T. Ikeda, M. Ushiyama, A. Nanbu, S. Kinoshita, M. Yoshimura.
Increased vitreous concentrations of human hepatocyte growth factor in proliferative diabetic retinopathy.
J Clin Endocrinol Metab, 84 (1999), pp. 659-662
[29.]
A. Cantón, R. Burgos, C. Hernández, C. Mateo, R.M. Segura, V. Mesa, et al.
Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy.
Br J Ophthalmol, 84 (2000), pp. 732-735
[30.]
R. Simó, A. Lecube, J. García-Arumí, E. Carrasco, C. Hernández.
Hepatocyte growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy: its relationship with vascular endothelial growth factor and retinopathy activity.
Diabetes Care, 27 (2004), pp. 287-288
[31.]
C. Hernández, E. Carrasco, J. García-Arumí, R.M. Segura, R. Simó.
Intravitreous levels of hepatocyte growth factor/scatter factor and vascular cell adhesion molecule-1 in the vitreous fluid of diabetic patients with proliferative retinopathy.
Diabetes Metab, 30 (2004), pp. 341-346
[32.]
R. Simó, M.T. Vidal, J. García-Arumí, E. Carrasco, N. García-Ramírez, R.M. Segura, et al.
Intravitreous hepatocyte growth factor in patients with proliferative diabetic retinopathy: a case-control study.
Diabetes Res Clin Pract, 71 (2006), pp. 36-44
[33.]
D.W. Dawson, O.V. Volpert, P. Gillis, S.E. Crawford, H. Xu, W. Benedict, et al.
Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.
Science, 285 (1999), pp. 245-248
[34.]
H. Liu, J.G. Ren, W.L. Cooper, C.E. Hawkins, M.R. Cowan, P.Y. Tong.
Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site.
Proc Natl Acad Sci USA, 27 (2004), pp. 6605-6610
[35.]
V. Stellmach, S.E. Crawford, W. Zhou, N. Bouck.
Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor.
Proc Natl Acad Sci USA, 98 (2001), pp. 2593-2597
[36.]
J. Spranger, M. Osterhoff, M. Reimann, M. Mohlig, M. Ristow, M.K. Francis, et al.
Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease.
Diabetes, 50 (2001), pp. 2641-2645
[37.]
N. Ogata, J. Tombran-Tink, M. Nishikawa, T. Nishimura, Y. Mitsuma, T. Sakamoto, et al.
Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment.
Am J Ophthalmol, 132 (2001), pp. 378-382
[38.]
R. Simó, A. Lecube, L. Sararols, J. García-Arumí, R.M. Segura, R. Casamitjana, et al.
Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients.
Diabetes Care, 25 (2002), pp. 2282-2286
[39.]
C. Hernández, E. Carrasco, R. Casamitjana, R. Deulofeu, J. García-Arumí, R. Simó.
Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects.
Diabetes Care, 28 (2005), pp. 1941-1947
Copyright © 2006. Sociedad Española de Endocrinología y Nutrición
